SERES THERAPEUTICS, INC. (NASDAQ:MCRB) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On March8, 2018, Seres Therapeutics, Inc. (the “Company”) announced its financial results for the year and quarter ended December31, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of this Form 8-K including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 2.02. | Regulation FD Disclosure. |
On March8, 2018, the Company posted an updated corporate slide presentation in the “Investors and Media” portion of its website at www.serestherapeutics.com including strategic and operation updates, preliminary results of the Phase 1b study of SER-262, and updated cash guidance. A copy of the slide presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.
| Item 2.02. | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibits relating to Item 2.02 and Item 2.02, respectively, shall be deemed to be furnished, and not filed:
Seres Therapeutics, Inc. ExhibitEX-99.1 2 d533714dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates – Positive SER-287 Phase 1b clinical and microbiome results support further development; Company plans to initiate next clinical trial in mid-2018 – – Preliminary Phase 1b study data obtained for SER-262,…To view the full exhibit click here
About SERES THERAPEUTICS, INC. (NASDAQ:MCRB)
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases.
